Yang Rick

10% Owner Yang Rick bought 207,100 shares of KRRO at $11.11 ($2.3M); stock down -77.6% from $51.36 high; 8 other insiders also bought in 14-day cluster.

Yang Rick (10% Owner) purchased 207,100 shares for $2,300,881.00 at $11.11 per share on 2026-03-10, bringing total holdings to 1,297,893 shares. This purchase occurs while KRRO trades at $11.50, off -77.6% from its 52-week high of $51.36, and coincides with a broader cluster pattern: 8 other insiders also bought within the same 14-day window. At the fundamentals level, the company reported revenue of $1,090,000.00 in the latest quarter with net income of $-18,061,000.00 and is unprofitable on a full-year basis, though annual revenue growth reached +181.5%. Yang's prior buy at KRRO on 2024-04-22 delivered negative 90-day returns (-18.6%), establishing a pattern of poorly-timed entry points at this ticker; his cross-ticker track record shows a 66.67% win rate on buys, but that prior miss at KRRO suggests caution. The multi-insider buy cluster against a deeply depressed valuation backdrop and unprofitable fundamentals warrants close monitoring of the company's path to profitability and any material operational or capital developments.

10% Owner Yang Rick bought 937,500 shares (18.4% increase) for $15.0M at $16.00; 14-insider cluster buy in 4-day-old IPO.

Yang Rick, a 10% owner, purchased 937,500 shares at $16.00 for $15,000,000.00, increasing his holdings from 5,097,538 to 6,035,038 shares (+18.4% vs pre-transaction holdings). The transaction occurred just 4 trading days after SpyGlass Pharma's recent listing, with the stock now trading at $27.55. This purchase is part of a cluster pattern: 14 other insiders also bought within the past 14 days, indicating coordinated accumulation at the IPO base. The filing contains a derivative-conversion transaction (Table II not yet populated); the shares_after figure represents only the Table I conversion, not the insider's total derivative position. The substantial buy volume across the insider group and the 72% markup from purchase price to current price suggests strong early confidence in the company's post-listing trajectory, though investors should note this is a very recent public company with limited trading history.

10% Owner Yang Rick buys 500,000 MBX shares for $8.0M; 14 insider cluster buy in 14 days

Yang Rick, a 10% owner, purchased 500,000 shares of MBX Biosciences at $16.00 on 2024-09-16, increasing his holdings by +16.1% from 3.11M to 3.61M shares. This $8.0M buy occurs within a broader pattern: 14 other insiders also purchased shares within the past 14 days, forming a cluster buy signal. With the stock trading at $21.50 as of 2024-09-17 (three trading days post-purchase), the stock has appreciated 34% above the transaction price, though the recent IPO listing limits longer-term context. The concentrated insider accumulation by a major shareholder alongside peer buying activity suggests alignment on valuation and company direction at a critical early stage.